The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation Reduction Act designed to reduce health care costs. HHS said the selected drugs accounted for $50.5 billion in total Part D gross covered prescription drug costs, or about 20%, of total Part D gross covered prescription drug costs between June 1, 2022, and May 31, 2023.

Drugmakers will need to sign agreements to join negotiations by Oct. 1, with the Center for Medicare & Medicaid Services making initial price offers in February 2024. The drugmakers will then have a month to accept or make a counteroffer. The resulting agreed-upon negotiated prices for the 10 drugs will be published by CMS by Sept. 1, 2024, with the prices taking effect Jan. 1, 2026. Additional drugs could be added to the list in future years.

Drugmakers that decline to negotiate the prices of selected drugs with CMS will be required to either pay an excise tax of up to 95% of U.S. sales or pull all its products from the Medicare and Medicaid markets.

Related News Articles

Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
As Congress weighs significant changes and cuts to Medicaid, the AHA today hosted a Capitol Hill briefing for congressional staff featuring hospital and health…
Headline
The House Budget Committee May 16 voted 21-16 against advancing the fiscal year 2025 budget reconciliation bill, with five Republicans joining all Democrats in…
Perspective
Public
Three key House committees — Energy and Commerce, Ways and Means, and Agriculture — after long debates and discussions this week advanced their portions of a…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The House Energy and Commerce Committee today advanced by a 30-24 vote along party lines its portion of the fiscal year 2025 reconciliation bill following a…